Table 2.
Effect of Mepolizumab on SBP-Ag–Induced Changes in Pulmonary Function
| Premepolizumab |
Postmepolizumab |
P Value Pre- vs. Postmepolizumab |
||||||
|---|---|---|---|---|---|---|---|---|
| Pre–SBP-Ag | 48 h Post–SBP-Ag | P Value | Pre–SBP-Ag | 48 h Post–SBP-Ag | P Value | Pre–SBP-Ag | Post–SBP-Ag | |
| FEV1, L* | 4.1 (3.4–4.7) | 4.0 (3.3–4.6) | 0.08 | 4.1 (3.4–4.7) | 4.0 (3.4–4.6) | 0.10 | 0.80 | 0.90 |
| FEV1, % predicted* | 96.3 (85.0–107.6) | 92.7 (82.1–103.3) | 0.04 | 95.1 (84.2–106.0) | 92.7 (84.0–101.4) | 0.08 | 0.38 | 1.00 |
| FVC, L* | 5.5 (4.4–6.5) | 5.4 (4.3–6.5) | 0.34 | 5.4 (4.4–6.4) | 5.4 (4.4–6.4) | 0.38 | 0.77 | 0.85 |
| FEV1/FVC* | 0.76 (0.70–0.82) | 0.76 (0.68–0.84) | 0.81 | 0.76 (0.70–0.83) | 0.75 (0.69–0.80) | 0.14 | 0.74 | 0.48 |
| PEFR, L/min* | 3.4 (2.7–4.0) | 3.3 (2.6–4.0) | 0.12 | 3.4 (2.7–4.1) | 3.2 (2.6–3.7) | 0.07 | 0.74 | 0.50 |
| Bronchodilator reversibility,† % | 6.8 ± 4.8 | 9.3 ± 5.0 | 0.05 | 6.7 ± 4.7 | 8.2 ± 5.1 | 0.23 | 0.94 | 0.41 |
| FeNO, ppb‡ | 40 (29–54) | 62 (49–77) | 0.003 | 32 (22–47) | 58 (39–85) | 0.0002 | 0.11 | 0.56 |
Definition of abbreviations: FeNO = fractional exhaled nitric oxide; PEFR = peak expiratory flow rate; ppb = parts per billion; SBP-Ag = segmental bronchoprovocation with allergen.
*
Least-squares means with 95% confidence intervals.
†
Albuterol (180 μg); data are shown as mean ± SD.
‡
Geometric means with 95% confidence intervals.